In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, X4 Pharmaceuticals Inc (NASDAQ: XFOR) closed at $3.51 down -1.27% from its previous closing price of $3.55. In other words, the price has decreased by -$1.27 from its previous closing price. On the day, 0.52 million shares were traded. XFOR stock price reached its highest trading level at $3.69 during the session, while it also had its lowest trading level at $3.43.
Ratios:
For a deeper understanding of X4 Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.48 and its Current Ratio is at 5.65. In the meantime, Its Debt-to-Equity ratio is 1.26 whereas as Long-Term Debt/Eq ratio is at 1.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 23 ’25 when Craig Adam R bought 86,206 shares for $2.90 per share. The transaction valued at 249,997 led to the insider holds 376,087 shares of the business.
Baldry Mark bought 1,032 shares of XFOR for $2,561 on May 16 ’25. The Chief Commercial Officer now owns 25,337 shares after completing the transaction at $2.48 per share. On Nov 15 ’24, another insider, Baldry Mark, who serves as the Chief Commercial Officer of the company, bought 13,404 shares for $0.34 each. As a result, the insider paid 4,598 and bolstered with 129,173 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 306465600. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.17 while its Price-to-Book (P/B) ratio in mrq is 1.43.
Stock Price History:
The Beta on a monthly basis for XFOR is 0.43, which has changed by -0.8085221 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, XFOR has reached a high of $26.83, while it has fallen to a 52-week low of $1.35. The 50-Day Moving Average of the stock is 2.70%, while the 200-Day Moving Average is calculated to be -36.89%.
Shares Statistics:
For the past three months, XFOR has traded an average of 3.98M shares per day and 3060680 over the past ten days. A total of 79.21M shares are outstanding, with a floating share count of 72.27M. Insiders hold about 8.77% of the company’s shares, while institutions hold 17.12% stake in the company. Shares short for XFOR as of 1760486400 were 1785248 with a Short Ratio of 0.45, compared to 1757894400 on 1892311. Therefore, it implies a Short% of Shares Outstanding of 1785248 and a Short% of Float of 7.9799999999999995.
Earnings Estimates
As of right now, 3.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.31 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$2.48 and -$4.3 for the fiscal current year, implying an average EPS of -$3.21. EPS for the following year is -$1.5, with 3.0 analysts recommending between -$1.13 and -$1.89.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $2.1M this quarter.It ranges from a high estimate of $2.52M to a low estimate of $1.7M. As of. The current estimate, X4 Pharmaceuticals Inc’s year-ago sales were $1.43MFor the next quarter, 4 analysts are estimating revenue of $2.77M. There is a high estimate of $3.3M for the next quarter, whereas the lowest estimate is $2.25M.
A total of 4 analysts have provided revenue estimates for XFOR’s current fiscal year. The highest revenue estimate was $35.44M, while the lowest revenue estimate was $34.3M, resulting in an average revenue estimate of $34.81M. In the same quarter a year ago, actual revenue was $2.56MBased on 4 analysts’ estimates, the company’s revenue will be $14.36M in the next fiscal year. The high estimate is $22.71M and the low estimate is $7M.
